Keywords: Pfizer, Prevnar, Over 50s, Pneumonia vaccine

Pfizer’s Prevnar 13 meets all endpoints in pivotal Ph III trials on over 50s

Article | 10 May 2011

Print This

Global drugs behemoth Pfizer (NYSE: PFE) says that the data from its two pivotal Phase III immunogenicity and safety trials ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in